

CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)
(the "**Company**")

**UNSOLICITED OFFER TO ACQUIRE SHARES IN CHINA CORD BLOOD CORPORATION
AND 7% SENIOR UNSECURED CONVERTIBLE NOTE DUE 2017**

The Board of Directors of the Company (the "**Board**") refers to the Company's announcement on 8 May 2015 on the Company's entry into a conditional purchase agreement dated 8 May 2015 (the "**Agreement**") with Golden Meditech Holdings Limited (the "**Purchaser**"), pursuant to which the Company agreed to sell, and the Purchaser agreed to purchase from the Company, 7,314,015 ordinary shares of par value US\$0.0001 per share in China Cord Blood Corporation ("**CCBC**") and 7% senior unsecured convertible note due 3 October 2017 issued by CCBC to the Company in the principal amount of US\$25 million (the convertible note and the shares collectively, the "**Assets**"). The transaction is subject to the approval of the Company's shareholders at a general meeting to be convened.

The Board wishes to announce that it has received an unsolicited offer from a third party to acquire the Assets (the "**Offer**").

After due and careful consideration, the Board has decided to reject the Offer. In coming to its decision, the Board considered a number of relevant commercial and legal factors, including the fact that the Company had already signed the binding Agreement with the Purchaser, the obligations agreed to be performed by the Company under the Agreement, the terms and conditions of the Offer and the relative timing and completion risks associated with each of the Agreement and the Offer.

Shareholders of the Company are advised to refrain from taking any action in relation to their shares of the Company which may be prejudicial to their interests, and to exercise caution when dealing in the shares of the Company.

By Order of the Board
CORDLIFE GROUP LIMITED

Mr. Yee Pinh Jeremy
Director
7 July 2015